 |
|
|
|
|
|
|
|
|
|
|
|
1 to 20 of 20 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Cutter G, Schneider L. on NEWS: Phase 3 Solanezumab Trials "Fail"—Is There a Silver Lining?, Quantitatively Assessing Lilly’s Solanezumab Trials Disclosure: More Than Meets the... 10 Sep 2012.
|
|
|
 |
|
|
Schneider L. on NEWS: No Pony in There: Bapi Fails Mild to Moderate ApoE4 Carriers, The topline results of the Phase 3, bapineuzumab trial 302 are disappointing but not surprising.... 24 Jul 2012.
|
|
|
|
|
|
Schneider L. on PAPER: Himeno E. et al., 2011, Very nice studies of how a classic small molecule with action at numerous receptors could be... 13 Mar 2011.
|
|
|
|
|
|
Schneider L. on NEWS: Lilly Halts IDENTITY Trials as Patients Worsen on Secretase Inhibitor, Semagacestat continues the streak of late-phase trial failures. All failed for lack of efficacy,... 24 Aug 2010.
|
|
|
|
|
|
Schneider L. on NEWS: Phoenix: Making Trials Work for Patient, Sponsor, Regulator, Suppose you have a registry or cohort of volunteers on whom you are gathering longitudinal data... 3 Mar 2010.
|
|
|
|
|
|
Schneider L. on PAPER: Ramanathan S. et al., 2009, Delusions, psychosis, and aggression that occur in a majority of patients with AD is difficult... 23 Nov 2009.
|
|
|
|
|
|
Schneider L. on PAPER: Olmos C. et al., 2009, Metrifonate is a prodrug hydrolyzed to dichlorvos, an irreversibly binding cholinesterase... 29 Apr 2009.
|
|
|
|
|
|
Schneider L. on SITE POLL: Are you in favor of ICAD going annual?, The Alzheimer's Association derives substantial publicity from ICAD. The Association may be... 21 Nov 2008.
|
|
|
|
|
|
Schneider L. on PAPER: Zhao X. et al., 2008, Unfortunately, it is now evident that the doses of tarenflurbil used in the large Phase 3... 18 Nov 2008.
|
|
|
|
|
|
Schneider L. on PAPER: Augustin S. et al., 2009, This work adds to the therapeutic rationale for the standardized ginkgo biloba extract EGb... 17 Nov 2008.
|
|
|
|
|
|
Schneider L. on PAPER: Roe CM. et al., 2008, This report also indirectly illustrates the complexities of using individual putative biomarkers... 17 Nov 2008.
|
|
|
|
|
|
Schneider L. on LIVE DISCUSSION: Leon Thal Symposium Webinar, My refrain for this meeting is that we need to look into history. The drug development programs... 3 Nov 2008.
|
|
|
|
|
|
Schneider L. on NEWS: Breakthrough or False Hope? Etanercept Case Report Draws Scrutiny, The media have been tripping over themselves about a single case report of what they have pegged... 24 Jan 2008.
|
|
|
|
|
|
Schneider L. on NEWS: Researchers Conclude: Cholinesterase Inhibitors Don’t Delay Alzheimer’s, A systematic review collects all relevant studies on a subject, integrates findings, and allows... 30 Nov 2007.
|
|
|
|
|
|
Schneider L. on NEWS: Philadelphia: European Trial of Alzhemed Ends, Marketing Morphs to Supplement, Reader advisory: These comments may appeal only to readers of a certain age, who remember... 27 Nov 2007.
|
|
|
|
|
|
Schneider L. on NEWS: FDA Deems U.S. Alzhemed Trial Results Inconclusive, This news story is a bit too optimistic and accepting of the company line. In truth, Neurochem... 14 Sep 2007.
|
|
|
|
|
|
Schneider L. on Early-Onset Familial AD: Alzheimer Disease in Mid-life, A modest proposal to address clinical trials for early-age-of-onset patients is to include them... 14 Jul 2007.
|
|
|
|
|
|
Schneider L. on NEWS: Crystal Ball for AD? Studies Quantitate Risk Factors, Markers of Progression, From a scientific perspective, it is desirable to be able to predict who develops dementia and... 4 Aug 2006.
|
|
|
|
|
|
Schneider L. on NEWS: Donepezil—Relief for Patients with Severe AD?, This Swedish nursing home trial demonstrates the practical utility of donepezil in severely... 3 Apr 2006.
|
|
|
|
|
|
Schneider L. on PAPER: Henderson DC. et al., 2005, Antipsychotic medications include haloperidol, thiothixine, trifluoperazine, perphenazine,... 12 Jan 2005.
|
|
|
|
|
|
|
1 to 20 of 20 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
See our latest Webinar: 
